Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer

Area of Science:

• Immunology
• Virology
• Oncology

Background:

• Oncolytic viruses are promising cancer immunotherapies but show variable patient responses.
• Understanding tumor immune microenvironment heterogeneity is crucial for enhancing oncolytic virotherapy efficacy.

Purpose of the Study:

• To design and construct an enhanced armed oncolytic virus (OV-5A) for improved cancer immunotherapy.
• To investigate the immune mechanisms underlying OV-5A treatment efficacy.
• To guide the development of combination therapies for oncolytic virotherapy.

Main Methods:

• Engineered OV-5A expressing five non-redundant genes.
• Evaluated OV-5A in mouse models, patient-derived xenografts, organoid co-cultures, and patient tissues.
• Utilized single-cell RNA sequencing (scRNA-seq) to analyze tumor immune microenvironment responses.

Main Results:

• OV-5A demonstrated robust anti-tumor immune responses across diverse models.
• Activated cooperative innate and adaptive immune responses against tumor cells.
• scRNA-seq identified immune signatures guiding combination therapy strategies.

Conclusions:

• OV-5A shows significant potential as an effective cancer immunotherapy agent.
• A data-driven approach using scRNA-seq can rationalize oncolytic virus design and combination therapy development.
• This strategy offers a pathway to more effective, personalized cancer treatments.